Search

Your search keyword '"Wildenbeest, Joanne"' showing total 155 results
Start Over Author "Wildenbeest, Joanne" Search Limiters Available in Library Collection
155 results on '"Wildenbeest, Joanne"'

1. Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection

Author

Sintoris, Sofia, Binkowska, Justyna M., Gillan, Jonathan L., Zuurbier, Roy P., Twynam-Perkins, Jonathan, Kristensen, Maartje, Melrose, Lauren, Parga, Paula Lusaretta, Rodriguez, Alicia Ruiz, Chu, Mei Ling, van Boeckel, Sara R., Wildenbeest, Joanne G., Bowdish, Dawn M. E., Currie, Andrew J., Thwaites, Ryan S., Schwarze, Jurgen, van Houten, Marlies A., Boardman, James P., Cunningham, Steve, Bogaert, Debby, and Davidson, Donald J.

Published
2024
Full Text
View/download PDF

2. Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic

Author

Boom, Trisja T., de Hoog, Marieke L.A., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie D., Fourie, Elandri, Sluiter-Post, Judith G.C., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Sanders, Elisabeth A.M., Eggink, Dirk, Reusken, Chantal, Bont, Louis J., Wildenbeest, Joanne G., van Houten, Marlies A., Duijts, Liesbeth, and Bruijning-Verhagen, Patricia C.J.L.

Published
2024
Full Text
View/download PDF

7. Serum and mucosal antibodymediated protection and identification of asymptomatic respiratory syncytial virus infection in community-dwelling older adults in Europe.

Author

Öner, Deniz, Vernhes, Charlotte, Balla-Jhagjhoorsingh, Sunita, Moureau, Annick, Crabbe, Marjolein, Salaun, Bruno, Bastian, Arangassery Rosemary, Thys, Kim, De Smedt, Jonathan, Ooft, Salo N., Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Christopher C., Verheij, Theo J. M., Drysdale, Simon B., Wildenbeest, Joanne G., Pollard, Andrew J., Openshaw, Peter J. M., and Bont, Louis

Subjects
RESPIRATORY syncytial virus infections, RESPIRATORY infections, RECEIVER operating characteristic curves, RESPIRATORY syncytial virus, OLDER people
Abstract

Introduction: Respiratory syncytial virus (RSV) causes acute respiratory tract infection (ARTI) and reinfects adults throughout life, posing a risk for hospitalization in older adults (>60 years) with frailty and comorbidities. Methods: To investigate serum and mucosal antibodies for protection against RSV infections, baseline serum samples were compared for RSV-pre- and -postfusion (F) binding, and RSV-A2 neutralizing IgG antibodies between symptomatic RSV-ARTI (N = 30), non-RSV (RSV negative) ARTI (N = 386), and no ARTI (N = 338). Mucosal RSV-pre-F IgA and IgG levels, as well as serum RSV-G IgG antibodies, were analyzed to determine their association with protection from symptomatic RSV-ARTI in a subset study. Results: Using a receiver operating characteristic (ROC) analysis, we established thresholds of 1.4- to 1.6-fold change (FC) for RSV-pre-F and -post-F, and RSV-A2 neutralizing IgG antibodies, respectively, enabling the identification of asymptomatic RSV cases with high sensitivity and specificity (>80% and >90%, respectively). As a result, serum RSV-pre-F, RSV-G IgG, and mucosal pre-F binding IgA antibodies showed correlations with protection against symptomatic RSV infection. RSV-pre-F IgG antibodies were correlated with protection from RSV infections irrespective of the symptoms. Discussion: This study provides insights into antibody-mediated protection for symptomatic RSV infection in a community-dwelling older-adult population and establishes a threshold to identify asymptomatic RSV infection using a datadriven approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Methodologie, Child Health, Onderzoek, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, JC onderzoeksprogramma Infectieziekten, Boom, Trisja T, de Hoog, Marieke L A, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie D, Fourie, Elandri, Sluiter-Post, Judith G C, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Sanders, Elisabeth A M, Eggink, Dirk, Reusken, Chantal, Bont, Louis J, Wildenbeest, Joanne G, van Houten, Marlies A, Duijts, Liesbeth, Bruijning-Verhagen, Patricia C J L, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Methodologie, Child Health, Onderzoek, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, JC onderzoeksprogramma Infectieziekten, Boom, Trisja T, de Hoog, Marieke L A, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie D, Fourie, Elandri, Sluiter-Post, Judith G C, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Sanders, Elisabeth A M, Eggink, Dirk, Reusken, Chantal, Bont, Louis J, Wildenbeest, Joanne G, van Houten, Marlies A, Duijts, Liesbeth, and Bruijning-Verhagen, Patricia C J L

Published
2024

9. Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection

Author

Infectieziekten onderzoek1 (Bont), Infectieziekten onderzoek3 (Bogaert), Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Onderzoek, Sintoris, Sofia, Binkowska, Justyna M., Gillan, Jonathan L., Zuurbier, Roy P., Twynam-Perkins, Jonathan, Kristensen, Maartje, Melrose, Lauren, Parga, Paula Lusaretta, Rodriguez, Alicia Ruiz, Chu, Mei Ling, van Boeckel, Sara R., Wildenbeest, Joanne G., Bowdish, Dawn M.E., Currie, Andrew J., Thwaites, Ryan S., Schwarze, Jurgen, van Houten, Marlies A., Boardman, James P., Cunningham, Steve, Bogaert, Debby, Davidson, Donald J., Infectieziekten onderzoek1 (Bont), Infectieziekten onderzoek3 (Bogaert), Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Onderzoek, Sintoris, Sofia, Binkowska, Justyna M., Gillan, Jonathan L., Zuurbier, Roy P., Twynam-Perkins, Jonathan, Kristensen, Maartje, Melrose, Lauren, Parga, Paula Lusaretta, Rodriguez, Alicia Ruiz, Chu, Mei Ling, van Boeckel, Sara R., Wildenbeest, Joanne G., Bowdish, Dawn M.E., Currie, Andrew J., Thwaites, Ryan S., Schwarze, Jurgen, van Houten, Marlies A., Boardman, James P., Cunningham, Steve, Bogaert, Debby, and Davidson, Donald J.

Published
2024

10. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

Author

CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Johnson, Mari, Chelysheva, Irina, Öner, Deniz, McGinley, Joseph, Lin, Gu-Lung, O'Connor, Daniel, Robinson, Hannah, Drysdale, Simon B, Gammin, Emma, Vernon, Sophie, Muller, Jill, Wolfenden, Helen, Westcar, Sharon, Anguvaa, Lazarus, Thwaites, Ryan S, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Aerssens, Jeroen, Openshaw, Peter J M, Pollard, Andrew J, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Johnson, Mari, Chelysheva, Irina, Öner, Deniz, McGinley, Joseph, Lin, Gu-Lung, O'Connor, Daniel, Robinson, Hannah, Drysdale, Simon B, Gammin, Emma, Vernon, Sophie, Muller, Jill, Wolfenden, Helen, Westcar, Sharon, Anguvaa, Lazarus, Thwaites, Ryan S, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Aerssens, Jeroen, Openshaw, Peter J M, and Pollard, Andrew J

Published
2024

11. Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands: a nationwide prospective observational study (the BRICK study)

Author

Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Intensive care patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, HEE, JC onderzoeksprogramma Methodologie, Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., Frederix, Geert J.W., Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Intensive care patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, HEE, JC onderzoeksprogramma Methodologie, Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., and Frederix, Geert J.W.

Published
2024

12. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, Buddingh, Emilie P, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, and Buddingh, Emilie P

Published
2024

13. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

Tulling, Adam J., Holierhoek, Marloes G., Jansen-Hoogendijk, Anja M., Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J., Oostenbrink, Rianne, Buysse, Corinne M.P., Bannier, Michiel A.G.E., Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C., Jacobs, Monique A.M., Kamps, Arvid W.A., van der Linden, Jan W., Lebon, Ankie, Oudshoorn, Johanna H., Tramper-Stranders, Gerdien A., Vastert, Sebastiaan J., Wieringa, Jantien W., Terheggen-Lagro, Suzanne W.J., Wildenbeest, Joanne G., von Asmuth, Erik G.J., van den Akker, Erik B., van Gijn, Marielle E., Lugthart, Gertjan, Buddingh, Emilie P., Tulling, Adam J., Holierhoek, Marloes G., Jansen-Hoogendijk, Anja M., Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J., Oostenbrink, Rianne, Buysse, Corinne M.P., Bannier, Michiel A.G.E., Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C., Jacobs, Monique A.M., Kamps, Arvid W.A., van der Linden, Jan W., Lebon, Ankie, Oudshoorn, Johanna H., Tramper-Stranders, Gerdien A., Vastert, Sebastiaan J., Wieringa, Jantien W., Terheggen-Lagro, Suzanne W.J., Wildenbeest, Joanne G., von Asmuth, Erik G.J., van den Akker, Erik B., van Gijn, Marielle E., Lugthart, Gertjan, and Buddingh, Emilie P.

Abstract

Children with Multisystem Inflammatory Syndrome in Children (MIS-C) can present with thrombocytopenia, which is a key feature of hemophagocytic lymphohistiocytosis (HLH). We hypothesized that thrombocytopenic MIS-C patients have more features of HLH. Clinical characteristics and routine laboratory parameters were collected from 228 MIS-C patients, of whom 85 (37%) were thrombocytopenic. Thrombocytopenic patients had increased ferritin levels; reduced leukocyte subsets; and elevated levels of ASAT and ALAT. Soluble IL-2RA was higher in thrombocytopenic children than in non-thrombocytopenic children. T-cell activation, TNF-alpha and IFN-gamma signaling markers were inversely correlated with thrombocyte levels, consistent with a more pronounced cytokine storm syndrome. Thrombocytopenia was not associated with severity of MIS-C and no pathogenic variants were identified in HLH-related genes. This suggests that thrombocytopenia in MIS-C is not a feature of a more severe disease phenotype, but the consequence of a distinct hyperinflammatory immunopathological process in a subset of children.

Published
2024

14. Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands:a nationwide prospective observational study (the BRICK study)

Author

Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., Frederix, Geert J.W., Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., and Frederix, Geert J.W.

Abstract

Background: The implementation of the approved respiratory syncytial virus (RSV) preventive interventions in immunisation programmes is advancing rapidly. Insight into healthcare costs of RSV-related paediatric intensive care unit (PICU) admissions is lacking, but of great importance to evaluate the impact of implementation. Therefore, this study aimed to determine the total annual RSV-related paediatric intensive care healthcare costs in the Netherlands. Methods: A nationwide prospective, observational, multicenter study was performed from September 2021 until June 2023. The total annual RSV-related healthcare costs on PICUs in the Netherlands were calculated using RSV-related costs (subgroup I) and consequential costs (subgroup II and III). Subgroup I comprised all PICU admitted infants ≤12 months of age with laboratory-confirmed RSV infection. Subgroup II and III consisted of postponed elective PICU admissions and refused acute PICU admissions due to RSV-related lack of PICU capacity.Findings: A total of 424 infants with RSV-related PICU admission were included. Median age at PICU admission was 46 days (IQR 25–89). The median length of PICU admission was 5 days (IQR 3–8). The total RSV-related PICU costs are € 3,826,386 in 2021–2022, and € 3,183,888 in 2022–2023. Potential costs averted by RSV preventive interventions is € 1.9 to € 2.6 million depending on season, and the duration of protection. Interpretation: RSV-related PICU admissions cost €3.1 to €3.8 million in the Netherlands during one season. The introduction of new RSV preventive interventions into the Dutch immunisation programme will generate significant cost-savings on PICUs and decreases the admission burden of PICUs.

Published
2024

15. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., Kretzschmar, Mirjam E., Bruijning-Verhagen, Patricia, Van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., Kretzschmar, Mirjam E., and Bruijning-Verhagen, Patricia

Abstract

Household studies provide an efficient means to study transmission of infectious diseases, enabling estimation of susceptibility and infectivity by person-type. A main inclusion criterion in such studies is usually the presence of an infected person. This precludes estimation of the hazards of pathogen introduction into the household. Here we estimate age- and time-dependent household introduction hazards together with within household transmission rates using data from a prospective household-based study in the Netherlands. A total of 307 households containing 1, 209 persons were included from August 2020 until March 2021. Follow-up of households took place between August 2020 and August 2021 with maximal follow-up per household mostly limited to 161 days. Almost 1 out of 5 households (59/307) had evidence of an introduction of SARS-CoV-2. We estimate introduction hazards and within-household transmission rates in our study population with penalized splines and stochastic epidemic models, respectively. The estimated hazard of introduction of SARS-CoV-2 in the households was lower for children (0-12 years) than for adults (relative hazard: 0.62; 95%CrI: 0.34-1.0). Estimated introduction hazards peaked in mid October 2020, mid December 2020, and mid April 2021, preceding peaks in hospital admissions by 1-2 weeks. Best fitting transmission models included increased infectivity of children relative to adults and adolescents, such that the estimated child-to-child transmission probability (0.62; 95%CrI: 0.40-0.81) was considerably higher than the adult-to-adult transmission probability (0.12; 95%CrI: 0.057-0.19). Scenario analyses indicate that vaccination of adults can strongly reduce household infection attack rates and that adding adolescent vaccination offers limited added benefit.

Published
2024

16. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, Bruijning-Verhagen, Patricia, Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, and Bruijning-Verhagen, Patricia

Published
2024

17. Outpatient respiratory syncytial virus infections and novel preventive interventions

Author

Infectieziekten onderzoek2 (Wildenbeest), Infection & Immunity, HAG Onderzoek, Child Health, Infectieziekten patientenzorg, Infectieziekten onderzoek1 (Bont), CTI Bont, Hak, Sarah F, Venekamp, Roderick P, Wildenbeest, Joanne G, Bont, Louis J, Infectieziekten onderzoek2 (Wildenbeest), Infection & Immunity, HAG Onderzoek, Child Health, Infectieziekten patientenzorg, Infectieziekten onderzoek1 (Bont), CTI Bont, Hak, Sarah F, Venekamp, Roderick P, Wildenbeest, Joanne G, and Bont, Louis J

Published
2024

18. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care

Author

Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Sheikh, Zakariya, Potter, Ellie, Li, You, Drysdale, Simon B, Wildenbeest, Joanne G, Robinson, Hannah, McGinley, Joseph, Lin, Gu-Lung, Öner, Deniz, Aerssens, Jeroen, Justicia-Grande, Antonio José, Martinón-Torres, Federico, Pollard, Andrew J, Bont, Louis, Nair, Harish, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Sheikh, Zakariya, Potter, Ellie, Li, You, Drysdale, Simon B, Wildenbeest, Joanne G, Robinson, Hannah, McGinley, Joseph, Lin, Gu-Lung, Öner, Deniz, Aerssens, Jeroen, Justicia-Grande, Antonio José, Martinón-Torres, Federico, Pollard, Andrew J, Bont, Louis, and Nair, Harish

Published
2024

19. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes

Author

Infectieziekten onderzoek2 (Wildenbeest), MS Verloskunde, Infection & Immunity, Infectieziekten patientenzorg, Child Health, CTI Bont, Infectieziekten onderzoek1 (Bont), Epidemiology & Health Economics, Data Science & Biostatistiek, RWE/Causal inference, Geboortecentrum voorzitterschap, Phijffer, Emily, de Bruin, Odette, Wildenbeest, Joanne G., Bont, Louis J., Sturkenboom, Miriam C.J.M., Van der Maas, Nicoline A.T., Ahmadizar, Fariba, Bloemenkamp, Kitty W.M., Infectieziekten onderzoek2 (Wildenbeest), MS Verloskunde, Infection & Immunity, Infectieziekten patientenzorg, Child Health, CTI Bont, Infectieziekten onderzoek1 (Bont), Epidemiology & Health Economics, Data Science & Biostatistiek, RWE/Causal inference, Geboortecentrum voorzitterschap, Phijffer, Emily, de Bruin, Odette, Wildenbeest, Joanne G., Bont, Louis J., Sturkenboom, Miriam C.J.M., Van der Maas, Nicoline A.T., Ahmadizar, Fariba, and Bloemenkamp, Kitty W.M.

Published
2024

20. IgG1 glycosylation highlights premature aging in Down syndrome.

Author

Streng, Bianca M. M., Van Coillie, Julie, Wildenbeest, Joanne G., Binnendijk, Rob S., Smits, Gaby, den Hartog, Gerco, Wang, Wenjun, Nouta, Jan, Linty, Federica, Visser, Remco, Wuhrer, Manfred, Vidarsson, Gestur, and Bont, Louis J.

Subjects
PREMATURE aging (Medicine), LIQUID chromatography-mass spectrometry, DOWN syndrome, GLYCOSYLATION, IMMUNE response, FUCOSYLATION
Abstract

Down syndrome (DS) is characterized by lowered immune competence and premature aging. We previously showed decreased antibody response following SARS‐CoV‐2 vaccination in adults with DS. IgG1 Fc glycosylation patterns are known to affect the effector function of IgG and are associated with aging. Here, we compare total and anti‐spike (S) IgG1 glycosylation patterns following SARS‐CoV‐2 vaccination in DS and healthy controls (HC). Total and anti‐Spike IgG1 Fc N‐glycan glycoprofiles were measured in non‐exposed adults with DS and controls before and after SARS‐CoV‐2 vaccination by liquid chromatography–mass spectrometry (LC–MS) of Fc glycopeptides. We recruited N = 44 patients and N = 40 controls. We confirmed IgG glycosylation patterns associated with aging in HC and showed premature aging in DS. In DS, we found decreased galactosylation (50.2% vs. 59.0%) and sialylation (6.7% vs. 8.5%) as well as increased fucosylation (97.0% vs. 94.6%) of total IgG. Both cohorts showed similar bisecting GlcNAc of total and anti‐S IgG1 with age. In contrast, anti‐S IgG1 of DS and HC showed highly comparable glycosylation profiles 28 days post vaccination. The IgG1 glycoprofile in DS exhibits strong premature aging. The combination of an early decrease in IgG1 Fc galactosylation and sialylation and increase in fucosylation is predicted to reduce complement activity and decrease FcγRIII binding and subsequent activation, respectively. The altered glycosylation patterns, combined with decreased antibody concentrations, help us understand the susceptibility to severe infections in DS. The effect of premature aging highlights the need for individuals with DS to receive tailored vaccines and/or vaccination schedules. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults

Author

Salaun, Bruno, primary, De Smedt, Jonathan, additional, Vernhes, Charlotte, additional, Moureau, Annick, additional, Öner, Deniz, additional, Bastian, Arangassery Rosemary, additional, Janssens, Michel, additional, Balla-Jhagjhoorsingh, Sunita, additional, Aerssens, Jeroen, additional, Lambert, Christophe, additional, Coenen, Samuel, additional, Butler, Christopher C., additional, Drysdale, Simon B., additional, Wildenbeest, Joanne G., additional, Pollard, Andrew J., additional, Openshaw, Peter J. M., additional, and Bont, Louis, additional

Published
2023
Full Text
View/download PDF

23. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults

Author

Mao, Zhuxin, Li, Xiao, Korsten, Koos, Bont, Louis, Butler, Christopher, Wildenbeest, Joanne, Coenen, Samuel, Hens, Niel, Bilcke, Joke, Beutels, Philippe, Nair, Harish, Campbell, Harry, Pollard, Andrew, Openshaw, Peter, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Swanson, Kena, Rizkalla, Bishoy, Vernhes, Charlotte, Gallichan, Scott, Aerssens, Jeroen, Kumar, Veena, Molero, Eva, Coenen, Samuel/0000-0002-1238-8052, Mao, Zhuxin, Li, Xiao, Korsten, Koos, BONTE, Luis, Butler, Christopher, Wildenbeest, Joanne, COENEN, Samuel, HENS, Niel, Bilcke, Joke, Beutels, Philippe, and RESCEU Investigators

Subjects
Financial Stress, Respiratory Syncytial Virus Infections, elderly, cost, EQ5D, Influenza, Human, Humans, Immunology and Allergy, Biology, Aged, flu, RSV, Middle Aged, outpatients, health-related quality of life, Hospitalization, productivity loss, Infectious Diseases, Respiratory Syncytial Virus, Human, influenza, prospective study, Independent Living, Quality of Life, Human medicine, Respiratory Syncytial Virus, costproductivity loss, Human
Abstract

Background Respiratory syncytial virus (RSV) and influenza virus infections result in a considerable mortality and morbidity among the aging population globally. Influenza vaccination for older adults before the seasonal influenza epidemic has been evaluated to be cost-effective in many countries. Interventions against RSV in older adults are in the pipeline, and evaluating their cost-effectiveness is crucial for decision making. To inform such evaluations, our aim was to estimate average costs and health-related quality of life (HRQoL) in older adults with RSV and influenza infection. Methods The European RESCEU observational cohort study followed 1040 relatively healthy community-dwelling older adults aged 60 years and older during 2 consecutive winter seasons. Health care resource use and HRQoL were collected and analyzed during RSV episodes, and also during influenza episodes. Country-specific unit cost data were mainly obtained from national databases. Direct costs were estimated from a patient, health care provider, and health care payers’ perspective, whereas indirect costs were estimated from a societal perspective. Due to small sample size, no formal statistical comparisons were made. Results Thirty-six RSV and 60 influenza episodes were reported, including 1 hospitalization. Means (median; first-third quartile) of €26.4 (€5.5; 0–47.3) direct and €4.4 (€0; 0–0) indirect costs were reported per nonhospitalized RSV episode, and €42.5 (€36; 3.3–66.7) direct and €32.1 (€0; 0–0) indirect costs per nonhospitalized influenza episode. For RSV episodes, the utility value decreased from 0.896 (0.928; 0.854–0.953) to 0.801 (0.854; 0.712–0.937) from preseason to 1 week after symptom onset; for influenza, the change was from 0.872 (0.895; 0.828–0.953) to 0.664 (0.686; 0.574–0.797). Conclusions The average costs and HRQoL estimates of older adults treated outside the hospital can be used to inform the design of future studies and the decision making regarding interventions to prevent RSV infection in older adults. Larger studies are needed to provide better country-specific and complementary cost estimates and to allow for formal statistical comparison of costs between RSV and influenza. Clinical Trials Registration NCT03621930.

Published
2022

24. Global molecular diversity of RSV – the “INFORM RSV” study

Author

Langedijk, Annefleur C., Lebbink, Robert Jan, Naaktgeboren, Christiana, Evers, Anouk, Viveen, Marco C., Greenough, Anne, Heikkinen, Terho, Stein, Renato T., Richmond, Peter, Martinón-Torres, Federico, Nunes, Marta, Hosoya, Mitsuaki, Keller, Christian, Bauck, Monika, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Hennus, Marije P., Jin, Hong, Tabor, David E., Tovchigrechko, Andrev, Ruzin, Alexey, Abram, Michael E., Wilkins, Deidre, Wildenbeest, Joanne G., Kragten-Tabatabaie, Leyla, Coenjaerts, Frank E. J., Esser, Mark T., and Bont, Louis J.

Published
2020
Full Text
View/download PDF

25. Single‐cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

Author

Zivanovic, Nevena, Öner, Deniz, Abraham, Yann, McGinley, Joseph, Drysdale, Simon B., Wildenbeest, Joanne G., Crabbe, Marjolein, Vanhoof, Greet, Thys, Kim, Thwaites, Ryan S., Robinson, Hannah, Bont, Louis, Openshaw, Peter J. M., Martinón‐Torres, Federico, Pollard, Andrew J., and Aerssens, Jeroen

Subjects
RESPIRATORY syncytial virus infections, INFANT diseases, RESPIRATORY syncytial virus, B cells
Abstract

Whereas most infants infected with respiratory syncytial virus (RSV) show no or only mild symptoms, an estimated 3 million children under five are hospitalized annually due to RSV disease. This study aimed to investigate biological mechanisms and associated biomarkers underlying RSV disease heterogeneity in young infants, enabling the potential to objectively categorize RSV‐infected infants according to their medical needs. Immunophenotypic and functional profiling demonstrated the emergence of immature and progenitor‐like neutrophils, proliferative monocytes (HLA‐DRLow, Ki67+), impaired antigen‐presenting function, downregulation of T cell response and low abundance of HLA‐DRLow B cells in severe RSV disease. HLA‐DRLow monocytes were found as a hallmark of RSV‐infected infants requiring hospitalization. Complementary transcriptomics identified genes associated with disease severity and pointed to the emergency myelopoiesis response. These results shed new light on mechanisms underlying the pathogenesis and development of severe RSV disease and identified potential new candidate biomarkers for patient stratification. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Contact With Young Children Increases the Risk of Respiratory Infection in Older Adults in Europe—the RESCEU Study

Author

Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Chris C, Pirçon, Jean-Yves, Verheij, Theo J M, Bont, Louis J, Wildenbeest, Joanne G, Butler, Christopher, Verheij, Theo, Bont, Louis, Wildenbeest, Joanne, Nair, Harish, Campbell, Harry, Beutels, Philippe, Openshaw, Peter, Pollard, Andrew, Molero, Eva, Meijer, Adam, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Aerssens, Jeroen, Swanson, Kena, Gruselle, Olivier, Leach, Amanda, Stoszek, Sonia, Demont, Clarisse, Gallichan, Scott, Pavot, Vincent, Vernhes, Charlotte, Kumar, Veena, and RESCEU Investigators

Subjects
Europe, Infectious Diseases, Child, Preschool, Odds Ratio, Humans, Infant, Immunology and Allergy, Human medicine, Respiratory Tract Infections, Biology, Aged
Abstract

Background Knowledge about how older adults get a respiratory infection is crucial for planning preventive strategies. We aimed to determine how contact with young children living outside of the household affects the risk of acute respiratory tract infections (ARTI) in community-dwelling older adults. Methods This study is part of the European RESCEU older adult study. Weekly surveillance was performed to detect ARTI throughout 2 winter seasons (2017-2018, 2018-2019). Child exposure, defined as having regular contact with children under 5 living outside of the subject’s household, was assessed at baseline. The average attributable fraction was calculated to determine the fraction of ARTI explained by exposure to these children. Results We prospectively established that 597/1006 (59%) participants experienced at least 1 ARTI. Child exposure increased the risk of all-cause ARTI (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.21 -2.08; P = .001). This risk was highest in those with the most frequent contact (aOR, 1.80; 95% CI, 1.23-2.63; P = .003). The average attributable fraction of child exposure explaining ARTI was 10% (95% CI, 5%-15%). Conclusions One of 10 ARTI in community-dwelling older adults is attributable to exposure to preschool children living outside of the household. Clinical Trials Registration NCT03621930.

Published
2021

27. T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults

Author

Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Salaun, Bruno, De Smedt, Jonathan, Vernhes, Charlotte, Moureau, Annick, Öner, Deniz, Bastian, Arangassery Rosemary, Janssens, Michel, Balla-Jhagjhoorsingh, Sunita, Aerssens, Jeroen, Lambert, Christophe, Coenen, Samuel, Butler, Christopher C, Drysdale, Simon B, Wildenbeest, Joanne G, Pollard, Andrew J, Openshaw, Peter J M, Bont, Louis, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Salaun, Bruno, De Smedt, Jonathan, Vernhes, Charlotte, Moureau, Annick, Öner, Deniz, Bastian, Arangassery Rosemary, Janssens, Michel, Balla-Jhagjhoorsingh, Sunita, Aerssens, Jeroen, Lambert, Christophe, Coenen, Samuel, Butler, Christopher C, Drysdale, Simon B, Wildenbeest, Joanne G, Pollard, Andrew J, Openshaw, Peter J M, and Bont, Louis

Published
2023

28. The impact of variant and vaccination on SARS-CoV-2 symptomatology:three prospective household cohorts

Author

Westerhof, Ilse, de Hoog, Marieke, Ieven, Margareta, Lammens, Christine, van Beek, Janko, Rozhnova, Ganna, Eggink, Dirk, Euser, Sjoerd, Wildenbeest, Joanne, Duijts, Liesbeth, van Houten, Marlies, Goossens, Herman, Giaquinto, Carlo, Bruijning‑Verhagen, Patricia, Westerhof, Ilse, de Hoog, Marieke, Ieven, Margareta, Lammens, Christine, van Beek, Janko, Rozhnova, Ganna, Eggink, Dirk, Euser, Sjoerd, Wildenbeest, Joanne, Duijts, Liesbeth, van Houten, Marlies, Goossens, Herman, Giaquinto, Carlo, and Bruijning‑Verhagen, Patricia

Abstract

Objectives: We compared age-stratified SARS-CoV-2 symptomatology of wild-type/Alpha vs Omicron BA.1/BA.2 variant infected individuals and the impact of COVID-19 booster vaccination on Omicron symptom burden. Methods: Data from three European prospective household cohorts were used (April 2020 to April 2021 and January to March 2022). Standardized outbreak protocols included (repeated) polymerase chain reaction testing, paired serology, and daily symptom scoring for all household members. Comparative analyses were performed on 346 secondary household cases from both periods. Results: Children <12 years (all unvaccinated) experienced more symptoms and higher severity scores during Omicron compared with wild-type/Alpha period (P ≤0.01). In adults, Omicron disease duration and severity were reduced (P ≤ 0.095). Omicron was associated with lower odds for loss of smell or taste (adjusted odds ratio [aOR]: 0.14; 95% CI 0.03-0.50) and higher but non-significant odds for upper respiratory symptoms, fever, and fatigue (aORs: 1.85-2.23). No differences were observed in disease severity or duration between primary vs booster series vaccinated adults (P ≥0.12). Conclusion: The Omicron variant causes higher symptom burden in children compared with wild-type/Alpha and lower in adults, possibly due to previous vaccination. A shift in symptoms occurred with reduction in loss of smell/taste for Omicron. No additional effect of booster vaccination on Omicron symptom burden was observed.

Published
2023

29. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children from Wild-type to Population Immunity: A Prospective Multicenter Cohort Study with Real-time Reporting

Author

Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., Van Woerden, Christiaan, Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., and Van Woerden, Christiaan

Published
2023

31. Are maternal vaccines effective and safe for mothers and infants?: A systematic review and meta-analysis of randomised controlled trials

Author

MS Verloskunde, Infectieziekten onderzoek2 (Wildenbeest), Infection & Immunity, RWE/Causal inference, Child Health, Infectieziekten patientenzorg, Data Science & Biostatistiek, CTI Bont, Infectieziekten onderzoek1 (Bont), de Bruin, Odette, Phijffer, Emily, Ahmadizar, Fariba, van der Maas, Nicoline, Wildenbeest, Joanne, Sturkenboom, Miriam, Bont, Louis, Bloemenkamp, Kitty, MS Verloskunde, Infectieziekten onderzoek2 (Wildenbeest), Infection & Immunity, RWE/Causal inference, Child Health, Infectieziekten patientenzorg, Data Science & Biostatistiek, CTI Bont, Infectieziekten onderzoek1 (Bont), de Bruin, Odette, Phijffer, Emily, Ahmadizar, Fariba, van der Maas, Nicoline, Wildenbeest, Joanne, Sturkenboom, Miriam, Bont, Louis, and Bloemenkamp, Kitty

Published
2023

32. Long term sequelae after SARS-CoV-2 infection in children: a household study

Author

Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, MS Infectieziekten, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Sluiter-Post, Judith G C, Fourie, Elandri, Wildenbeest, Joanne G, van Lelyveld, Steven F L, Bruijning-Verhagen, Patricia C J L, van Houten, Marianne A, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, MS Infectieziekten, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Sluiter-Post, Judith G C, Fourie, Elandri, Wildenbeest, Joanne G, van Lelyveld, Steven F L, Bruijning-Verhagen, Patricia C J L, and van Houten, Marianne A

Published
2023

33. Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study

Author

Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Cluster B, Immuno/reuma patientenzorg, Child Health, Haematologie patientenzorg, Poli Van Creveldkliniek Medisch, SCT patientenzorg, Regenerative Medicine and Stem Cells, MS Oogheelkunde, Onderzoek, MMB Medische Staf, Immuno/reuma ERN, Ohm, Milou, van Straalen, Joeri W, de Joode-Smink, Gerrie, van Montfrans, Joris, Bartels, Marije, van Wildenbeest, Joanne G, Lindemans, Caroline A, Wennink, Roos Aw, de Boer, Joke H, Sanders, Elisabeth Am, Verduyn-Lunel, Frans M, Berbers, Guy Am, Wulffraat, Nico M, Jansen, Marc H A, Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Cluster B, Immuno/reuma patientenzorg, Child Health, Haematologie patientenzorg, Poli Van Creveldkliniek Medisch, SCT patientenzorg, Regenerative Medicine and Stem Cells, MS Oogheelkunde, Onderzoek, MMB Medische Staf, Immuno/reuma ERN, Ohm, Milou, van Straalen, Joeri W, de Joode-Smink, Gerrie, van Montfrans, Joris, Bartels, Marije, van Wildenbeest, Joanne G, Lindemans, Caroline A, Wennink, Roos Aw, de Boer, Joke H, Sanders, Elisabeth Am, Verduyn-Lunel, Frans M, Berbers, Guy Am, Wulffraat, Nico M, and Jansen, Marc H A

Published
2023

34. Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study

Author

Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Arts-assistenten Kinderen, Immuno/reuma patientenzorg, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Cluster B, Haematologie patientenzorg, Poli Van Creveldkliniek Medisch, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, SCT patientenzorg, Regenerative Medicine and Stem Cells, MDL, MS Oogheelkunde, MS Reumatologie/Immunologie/Infectie, Onderzoek, MMB Medische Staf, Immuno/reuma ERN, Ohm, Milou, van Straalen, Joeri W, Zijlstra, Marieke, de Joode-Smink, Gerrie, Jasmijn Sellies, Anne, Swart, Joost F, Vastert, Sebastiaan J, van Montfrans, Joris M, Bartels, Marije, van Royen-Kerkhof, Annet, Wildenbeest, Joanne G, Lindemans, Caroline A, Wolters, Victorien, Wennink, Roos A W, de Boer, Joke H, Knol, Mirjam J, Heijstek, Marloes W, Sanders, Elisabeth A M, Verduyn-Lunel, Frans M, Berbers, Guy A M, Wulffraat, Nico M, Jansen, Marc H A, Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Arts-assistenten Kinderen, Immuno/reuma patientenzorg, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Cluster B, Haematologie patientenzorg, Poli Van Creveldkliniek Medisch, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, SCT patientenzorg, Regenerative Medicine and Stem Cells, MDL, MS Oogheelkunde, MS Reumatologie/Immunologie/Infectie, Onderzoek, MMB Medische Staf, Immuno/reuma ERN, Ohm, Milou, van Straalen, Joeri W, Zijlstra, Marieke, de Joode-Smink, Gerrie, Jasmijn Sellies, Anne, Swart, Joost F, Vastert, Sebastiaan J, van Montfrans, Joris M, Bartels, Marije, van Royen-Kerkhof, Annet, Wildenbeest, Joanne G, Lindemans, Caroline A, Wolters, Victorien, Wennink, Roos A W, de Boer, Joke H, Knol, Mirjam J, Heijstek, Marloes W, Sanders, Elisabeth A M, Verduyn-Lunel, Frans M, Berbers, Guy A M, Wulffraat, Nico M, and Jansen, Marc H A

Published
2023

35. The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Methodologie, Child Health, Epi Infectieziekten Team 2, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, JC onderzoeksprogramma Infectieziekten, Westerhof, Ilse, de Hoog, Marieke, Ieven, Margareta, Lammens, Christine, van Beek, Janko, Rozhnova, Ganna, Eggink, Dirk, Euser, Sjoerd, Wildenbeest, Joanne, Duijts, Liesbeth, van Houten, Marlies, Goossens, Herman, Giaquinto, Carlo, Bruijning-Verhagen, Patricia, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Methodologie, Child Health, Epi Infectieziekten Team 2, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, JC onderzoeksprogramma Infectieziekten, Westerhof, Ilse, de Hoog, Marieke, Ieven, Margareta, Lammens, Christine, van Beek, Janko, Rozhnova, Ganna, Eggink, Dirk, Euser, Sjoerd, Wildenbeest, Joanne, Duijts, Liesbeth, van Houten, Marlies, Goossens, Herman, Giaquinto, Carlo, and Bruijning-Verhagen, Patricia

Published
2023

36. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Author

Infectieziekten onderzoek1 (Bont), Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, CTI Bont, Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, Bont, Louis, Infectieziekten onderzoek1 (Bont), Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, CTI Bont, Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, and Bont, Louis

Published
2023

37. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Immuno/reuma patientenzorg, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, Bruijning-Verhagen, Patricia, Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Immuno/reuma patientenzorg, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, and Bruijning-Verhagen, Patricia

Published
2023

38. Decreased antibody response after severe acute respiratory syndrome coronavirus 2 vaccination in patients with Down syndrom

Author

Streng, Bianca M M, Bont, Marin, Delemarre, Eveline M, Binnendijk, Rob S, Smit, Gaby, den Hartog, Gerco, Coppus, Antonia M W, de Vries, Esther, Weijerman, Michel E, Lamberts, Regina, de Graaf, Gert, van der Klis, Fiona R, Vidarsson, Gestur, Rave, Neele, Bont, Louis J, Wildenbeest, Joanne G, LS IRAS Tox Algemeen, Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, AII - Inflammatory diseases, Landsteiner Laboratory, LS IRAS Tox Algemeen, Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Huisarts & Ziekenhuis, and Tranzo, Scientific center for care and wellbeing

Subjects
Adult, COVID-19 Vaccines, COVID-19 vaccination, SARS-CoV-2, COVID-19/prevention & control, Messenger, Vaccination, COVID-19, antibody response, Antibodies, Viral, Antibodies, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Infectious Diseases, Antibody Formation, Immunology and Allergy, Humans, RNA, RNA, Messenger, Viral, Prospective Studies, Down Syndrome, BNT162 Vaccine
Abstract

The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1–specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]–1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. Clinical Trials Registration NCT05145348.

Published
2022

39. Additional file 1 of Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study

Author

Ohm, Milou, van Straalen, Joeri W, de Joode-Smink, Gerrie, van Montfrans, Joris, Bartels, Marije, van Wildenbeest, Joanne G, Lindemans, Caroline A, Wennink, Roos AW, de Boer, Joke H, Sanders, Elisabeth AM, Verduyn-Lunel, Frans M, Berbers, Guy AM, Wulffraat, Nico M, and Jansen, Marc H.A.

Abstract

Supplementary Material 1

Published
2023
Full Text
View/download PDF

41. Additional file 2 of Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study

Author

Ohm, Milou, van Straalen, Joeri W, de Joode-Smink, Gerrie, van Montfrans, Joris, Bartels, Marije, van Wildenbeest, Joanne G, Lindemans, Caroline A, Wennink, Roos AW, de Boer, Joke H, Sanders, Elisabeth AM, Verduyn-Lunel, Frans M, Berbers, Guy AM, Wulffraat, Nico M, and Jansen, Marc H.A.

Abstract

Supplementary Material 2

Published
2023
Full Text
View/download PDF

45. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

Author

Derksen-Lazet, Nicole D, Parmentier, Corline E J, Wildenbeest, Joanne G, Bont, Louis J, Derksen-Lazet, Nicole, Parmentier, Corline, Bont, Louis, Wildenbeest, Joanne, Nair, Harish, Campbell, Harry, Beutels, Philippe, Pollard, Andrew, Openshaw, Peter, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Kena Swanson, Tin Tin Myint, Rizkalla, Bishoy, Vernhes, Charlotte, Gallichan, Scott, Aerssens, Jeroen, Kumar, Veena, Molero, Eva, and Investigators, RESCEU

Subjects
Adult, Europe, Immunocompromised Host, Infectious Diseases, Respiratory Syncytial Virus, Human, Immunology and Allergy, Humans, Respiratory Syncytial Virus Infections, Patient Participation, Child, Aged
Abstract

Respiratory syncytial virus (RSV) causes a substantial disease burden among children, elderly and immunocompromised adults. Recognition of patient involvement in research is gradually increasing. Most research is being carried out without active patient involvement other than patients participating as study subjects, and most knowledge gained through research only partially reaches the general public. Since 2016, the RSV Patient Advisory Board has officially been involved as an advisory group in the Respiratory Syncytial Virus Consortium in Europe (RESCEU). What started as a small single-center initiative, is now growing towards an international organization providing patient perspectives as inputs to scientists, and improving awareness of RSV. This article summarizes the history, current role, and future aims of the RSV Patient Advisory Board as an advocate to improve patient involvement in research. RSV patients and their representatives are important stakeholders in setting the global research agenda, and educating patients, professionals, and the general public.

Published
2022

46. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic

Author

de Hoog, Marieke L A, Sluiter-Post, Judith G C, Westerhof, Ilse, Fourie, Elandri, Heuvelman, Valerie D, Boom, Trisja T, Euser, Sjoerd M, Badoux, Paul, Reusken, Chantal, Bont, Louis J, Sanders, Elisabeth A M, Jaddoe, Vincent W V, Herpers, Bjorn L, Eggink, Dirk, Wildenbeest, Joanne G, Duijts, Liesbeth, van Houten, Marlies A, Bruijning-Verhagen, Patricia C J L, Medical Microbiology and Infection Prevention, AII - Infectious diseases, and Pediatrics

Subjects
Adult, Parents, Male, COVID-19 Vaccines, Adolescent, SARS-CoV-2, COVID-19, General Medicine, Cohort Studies, COVID-19 Testing, SDG 3 - Good Health and Well-being, Seroepidemiologic Studies, Humans, Female, Child, Pandemics
Abstract

ImportanceIn the early COVID-19 pandemic, SARS-CoV-2 testing was only accessible and recommended for symptomatic persons or adults. This restriction hampered assessment of the true incidence of SARS-CoV-2 infection in children as well as detailed characterization of the SARS-CoV-2 disease spectrum and how this spectrum compared with that of other common respiratory illnesses.ObjectiveTo estimate the community incidence of SARS-CoV-2 infection in children and parents and to assess the symptoms and symptom severity of respiratory illness episodes involving SARS-CoV-2–positive test results relative to those with SARS-CoV-2–negative test results.Design, Setting, and ParticipantsThis cohort study randomly selected Dutch households with at least 1 child younger than 18 years. A total of 1209 children and adults from 307 households were prospectively followed up between August 25, 2020, and July 29, 2021, covering the second and third waves of the COVID-19 pandemic. Participation included SARS-CoV-2 screening at 4- to 6-week intervals during the first 23 weeks of participation (core study period; August 25, 2020, to July 29, 2021). Participants in all households finishing the core study before July 1, 2021, were invited to participate in the extended follow-up and to actively report respiratory symptoms using an interactive app until July 1, 2021. At new onset of respiratory symptoms or a SARS-CoV-2 positive test result, a household outbreak study was initiated, which included daily symptom recording, repeated polymerase chain reaction testing (nose-throat swabs and saliva and fecal samples), and SARS-CoV-2 antibody measurement (paired dried blood spots) in all household members. Outbreaks, households, and episodes of respiratory illness were described as positive or negative depending on SARS-CoV-2 test results. Data on participant race and ethnicity were not reported because they were not uniformly collected in the original cohorts and were therefore not representative or informative.ExposuresSARS-CoV-2–positive and SARS-CoV-2–negative respiratory illness episodes.Main Outcomes and MeasuresAge-stratified incidence rates, symptoms, and symptom severity for SARS-CoV-2–positive and SARS-CoV-2–negative respiratory illness episodes.ResultsAmong 307 households including 1209 participants (638 female [52.8%]; 403 [33.3%] aged P Conclusions and RelevanceIn this cohort study, during the first pandemic year when mostly partial or full in-person learning occurred, the SARS-CoV-2 incidence rate in children was substantially higher than estimated from routine testing or seroprevalence data and was similar to that of adult household members. Unlike in unvaccinated adults, SARS-CoV-2 symptoms and symptom severity in children were similar to other common respiratory illnesses. These findings may prove useful when developing pediatric COVID-19 vaccine recommendations.

Published
2022

47. Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU)

Author

Jefferies, Kimberley, Drysdale, Simon B, Robinson, Hannah, Clutterbuck, Elizabeth Ann, Blackwell, Luke, McGinley, Joseph, Lin, Gu-Lung, Galal, Ushma, Nair, Harish, Aerssens, Jeroen, Öner, Deniz, Langedijk, Annefleur, Bont, Louis, Wildenbeest, Joanne G, Martinon-Torres, Federico, Rodríguez-Tenreiro Sánchez, Carmen, Nadel, Simon, Openshaw, Peter, Thwaites, Ryan, Widjojoatmodjo, Myra, Zhang, Linong, Nguyen, Thi Lien-Anh, Giaquinto, Carlo, Giordano, Giuseppe, Baraldi, Eugenio, Pollard, Andrew J, Campbell, Harry, Beutels, Philippe, Wildenbeest, Joanne, Bogaert, Debby, Pollard, Andrew, Klenerman, Paul, Sande, Charles, Snape, Matthew, Drysdale, Simon, Butler, Christopher, Diaz, Carlos, Molero, Eva, Wedzicha, Jadwicha, Martinón-Torres, Federico, Rodriguez-Tenreiro, Carmen, Heikkinen, Terho, Meijer, Adam, Sanders, Elisabeth, Fischer, Thea Kølsen, van den Berge, Maarten, Hackett, Judy, Dillon, Laura, Knirsch, Charles, Lopez, Antonio Gonzalez, Gallichan, Scott, Demont, Clarisse, Hillson, Eric, Rosen, Brian, and Investigators, Respiratory Syncytial Virus Consortium in Europe (RESCEU)

Subjects
Epigenomics, Male, Proteomics, Respiratory syncytial virus, Severity of Illness Index, 0302 clinical medicine, Risk Factors, Nasopharynx, Surveys and Questionnaires, Immunology and Allergy, 030212 general & internal medicine, Respiratory Tract Infections, Acute respiratory tract infection, Netherlands, media_common, Respiratory tract infections, Convalescence, Viral Load, 3. Good health, Europe, Infectious Diseases, Specimen collection, Disease Progression, Epigenetics, Female, Viral load, Human, medicine.medical_specialty, media_common.quotation_subject, Respiratory Syncytial Virus Infections, 03 medical and health sciences, Internal medicine, Severity of illness, medicine, Humans, Metabolomics, Transcriptomics, business.industry, Case-control study, Infant, medicine.disease, Comorbidity, United Kingdom, 030228 respiratory system, Biomarkers, Case-Control Studies, Respiratory Syncytial Virus, Human, Spain, Transcriptome, business
Abstract

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. Respiratory syncytial virus (RSV) is the leading viral pathogen associated with acute lower respiratory tract infection and hospitalization in children < 5 years of age worldwide. While there are known clinical risk factors for severe RSV infection, the majority of those hospitalized are previously healthy infants. There is consequently an unmet need to identify biomarkers that predict host response, disease severity, and sequelae. The primary objective is to identify biomarkers of severe RSV acute respiratory tract infection (ARTI) in infants. Secondary objectives include establishing biomarkers associated with respiratory sequelae following RSV infection and characterizing the viral load, RSV whole-genome sequencing, host immune response, and transcriptomic, proteomic, metabolomic and epigenetic signatures associated with RSV disease severity. Six hundred thirty infants will be recruited across 3 European countries: the Netherlands, Spain, and the United Kingdom. Participants will be recruited into 2 groups: (1) infants with confirmed RSV ARTI (includes upper and lower respiratory tract infections), 500 without and 50 with comorbidities; and (2) 80 healthy controls. At baseline, participants will have nasopharyngeal, blood, buccal, stool, and urine samples collected, plus complete a questionnaire and 14-day symptom diary. At convalescence (7 weeks ± 1 week post-ARTI), specimen collection will be repeated. Laboratory measures will be correlated with symptom severity scores to identify corresponding biomarkers of disease severity. CLINICAL TRIALS REGISTRATION: NCT03756766.

Published
2020

48. Low Sensitivity of BinaxNOW RSV in Infants

Author

Zuurbier, Roy P, Bont, Louis J, Langedijk, Annefleur C, Hamer, Mirjam, Korsten, Koos, Drysdale, Simon B, Snape, Matthew D, Robinson, Hannah, Pollard, Andrew J, Martinón-Torres, Federico, Rodríguez-Tenreiro Sánchez, Carmen, Gómez-Carballa, Alberto, Dacosta-Urbieta, Ana Isabel, Heikkinen, Terho, Cunningham, Steve, van Houten, Marlies A, Wildenbeest, Joanne G, Zuurbier, Roy, Bont, Louis, Langedijk, Annefleur, van Houten, Marlies, Wildenbeest, Joanne, Drysdale, Simon, Snape, Matthew, Pollard, Andrew, Dacosta-Urbieta, Ana, Nair, Harish, Campbell, Harry, Openshaw, Peter, Beutels, Philippe, Molero, Eva, Meijer, Adam, Kølsen Fischer, Thea, van den Berge, Maarten, Giaquinto, Carlo, Esser, Mark, Knirsch, Charles, Leach, Amanda, Gallichan, Scott, Aerssens, Jeroen, Rosen, Brian, and Investigators, RESCEU

Subjects
Male, medicine.medical_specialty, Adolescent, medicine.drug_class, Point-of-Care Systems, Point-of-care testing, Antibiotics, Respiratory Syncytial Virus Infections, Sensitivity and Specificity, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Severity of illness, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Pathology, Molecular, Respiratory system, Child, Antigens, Viral, Reference standards, 0303 health sciences, Respiratory tract infections, 030306 microbiology, business.industry, Gold standard (test), Confidence interval, 3. Good health, Hospitalization, Infectious Diseases, Case-Control Studies, Child, Preschool, Respiratory Syncytial Virus, Human, Female, Reagent Kits, Diagnostic, business
Abstract

Background Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular diagnosis. Methods We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard. Results One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% (95% confidence interval [CI], 3.3%–16.5%) and a specificity of 100% (95% CI, 96.2%–100%). Sensitivity was low in all subgroups. Conclusions We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used and interpreted with caution.

Published
2020

49. World Health Organization influenza-like illness underestimates the burden of respiratory syncytial virus infection in community-dwelling older adults

Author

Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Chris C, Verheij, Theo J M, Bont, Louis J, Wildenbeest, Joanne G, Butler, Christopher, Verheij, Theo, Bont, Louis, Wildenbeest, Joanne, Nair, Harish, Campbell, Harry, Cunningham, Steve, Beutels, Philippe, Openshaw, Peter, Pollard, Andrew, Molero, Eva, Meijer, Adam, Martinon-Torres, Federico, Heikkinen, Terho, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Öner, Deniz, Aerssens, Jeroen, Swanson, Kena, Leach, Amanda, Stoszek, Sonia, Demont, Clarisse, Gallichan, Scott, Kumar, Veena, Falsey, Ann, and RESCEU Investigators

Subjects
Fever, Infant, virus diseases, Respiratory Syncytial Virus Infections, World Health Organization, Cohort Studies, Infectious Diseases, Virus Diseases, Respiratory Syncytial Virus, Human, Influenza, Human, Humans, Immunology and Allergy, Independent Living, Prospective Studies, Human medicine, Respiratory Tract Infections, Biology, Aged
Abstract

Background Respiratory syncytial virus (RSV) surveillance is heavily dependent on the influenza-like illness (ILI) case definition from the World Health Organization (WHO). Because ILI includes fever in its syndromic case definition, its ability to accurately identify acute respiratory tract infections (ARTI) caused by RSV in older adults is uncertain. Methods The accuracy of the WHO ILI and a modified ILI (requiring only self-reported fever) case definitions in identifying patients with PCR-confirmed RSV-ARTI was evaluated in community-dwelling older adults (≥60 years) from the prospective European RESCEU cohort study. Results Among 1040 participants, 750 ARTI episodes were analyzed including 36 confirmed RSV-ARTI. Due to a general lack of fever, sensitivity for RSV-ARTI was 33% for modified ILI and 11% for ILI. The area under the curve for both ILI definitions was 0.52 indicating poor discrimination for RSV. RSV-ARTI could not be distinguished from all other ARTI based on clinical symptoms. Conclusions The use of ILI underestimated the occurrence of RSV-ARTI in community-dwelling older adults up to 9-fold (11% sensitivity). Because worldwide RSV surveillance depends largely on ILI, there is an urgent need for a better approach to measure the occurrence of RSV disease and the impact of future RSV vaccine introduction. Clinical Trials Registration. NCT03621930.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results